EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Sevoflurane alleviates myocardial fibrosis by targeting the YTHDF1/AXL/ferroptosis axis

Qiong Song, Lu Li, Wei Zhang, Jiaying Liu, Xiaochen Yang, Yanqing Lv, Jianzhuang Gong, Lijun Wang, Nai Sun

Letters in Drug Design & Discovery · 2026-09 · 23 (9) · 100607

DOI: 10.1016/j.lddd.2026.100607 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Letters in Drug Design & Discovery, 2026-09. Verfasst von Qiong Song und 8 weiteren Autor:innen. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Henan Provincial Science and Technology Research Project.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Myocardial fibrosis is a central pathological feature of multiple cardiovascular diseases progressing to heart failure. The molecular mechanisms underlying its development remain incompletely understood, and effective therapeutic targets are lacking.

Objective

This study aimed to investigate whether sevoflurane alleviates myocardial fibrosis and to elucidate the underlying molecular mechanisms involving the YTHDF1/AXL/ferroptosis axis.

Methods

A rat model of myocardial fibrosis induced by abdominal aortic constriction (AAC) was established, with groups designated as sham operation (Sham), sevoflurane alone (S), AAC model (AAC), and AAC + sevoflurane (AAC + S). The degree of fibrosis was evaluated by Masson staining and immunohistochemistry. In vitro, human atrial fibroblasts (HAFs) were induced to undergo fibrosis by angiotensin II (Ang-II). Combined with sevoflurane intervention, ferroptosis inhibitor (Fer-1) treatment, YTHDF1 overexpression/knockdown, and PI3K inhibitor treatment, Western blot, qPCR, and detection of ferroptosis indicators (e.g., Fe 2+ , MDA) were used to analyze the related regulatory mechanisms.

Results

In vivo experiments showed that sevoflurane significantly reduced cardiomyocyte surface area, left ventricular collagen volume fraction, and the expression of type I/III collagen in AAC rats, thereby improving myocardial fibrosis. In vitro, sevoflurane promoted ferroptosis in Ang-II-induced HAFs, as evidenced by increased levels of Fe 2+ , MDA, and ROS; decreased activities of SOD, GSH, and GSH-Px; downregulated expression of GPX4 and SLC7A11; and upregulated expression of NCOA4. Meanwhile, sevoflurane inhibited the expression of fibrosis-related proteins (α-SMA, Collagen I, Collagen III). Blocking ferroptosis (via Fer-1 intervention) attenuated the anti-fibrotic effect of sevoflurane. Mechanistically, sevoflurane downregulated the expression of YTHDF1 and AXL and inhibited the activation of the PI3K/AKT signaling pathway. Overexpression of YTHDF1 reversed sevoflurane-induced ferroptosis and its anti-fibrotic effect. YTHDF1/AXL regulated fibrosis by activating the PI3K/AKT pathway, and this effect could be blocked by a PI3K inhibitor.

Conclusion

Sevoflurane attenuates myocardial fibrosis by downregulating the YTHDF1/AXL axis, suppressing PI3K/AKT signaling, and inducing ferroptosis in cardiac fibroblasts, providing novel therapeutic targets for myocardial fibrosis.

Förderung

  • Henan Provincial Science and Technology Research Project

Zitieren

APA

Song, Q., Li, L., Zhang, W., Liu, J., Yang, X., Lv, Y., Gong, J., Wang, L., & Sun, N. (2026). Sevoflurane alleviates myocardial fibrosis by targeting the YTHDF1/AXL/ferroptosis axis. Letters in Drug Design & Discovery, 23(9), 100607. https://doi.org/10.1016/j.lddd.2026.100607

Vancouver

Song Q, Li L, Zhang W, Liu J, Yang X, Lv Y, et al. Sevoflurane alleviates myocardial fibrosis by targeting the YTHDF1/AXL/ferroptosis axis. Letters in Drug Design & Discovery. 2026;23(9):100607. doi:10.1016/j.lddd.2026.100607

BibTeX
@article{Song2026,
  author = {Song, Qiong and Li, Lu and Zhang, Wei and Liu, Jiaying and Yang, Xiaochen and Lv, Yanqing and Gong, Jianzhuang and Wang, Lijun and Sun, Nai},
  title = {Sevoflurane alleviates myocardial fibrosis by targeting the YTHDF1/AXL/ferroptosis axis},
  journal = {Letters in Drug Design & Discovery},
  year = {2026},
  volume = {23},
  number = {9},
  pages = {100607},
  doi = {10.1016/j.lddd.2026.100607}
}
Kostenlos starten →